Zipalertinib
A tyrosine kinase inhibitor used in cancer treatment
| Zipalertinib | |
|---|---|
[[File: | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Zipalertinib is a tyrosine kinase inhibitor (TKI) that is being investigated for its potential use in the treatment of various types of cancer. It is designed to target specific mutations in cancer cells, thereby inhibiting their growth and proliferation.
Mechanism of Action[edit]
Zipalertinib functions by selectively inhibiting the activity of certain tyrosine kinases, which are enzymes involved in the signaling pathways that regulate cell division and survival. By blocking these enzymes, zipalertinib can prevent the growth of cancer cells that rely on these pathways for proliferation.
Clinical Development[edit]
Zipalertinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with different types of cancer, including non-small cell lung cancer (NSCLC) and other solid tumors. These trials aim to determine the optimal dosing regimen and to identify any potential side effects associated with the drug.
Pharmacokinetics[edit]
The pharmacokinetic profile of zipalertinib includes its absorption, distribution, metabolism, and excretion. Understanding these parameters is crucial for determining the appropriate dosing schedule and for predicting potential drug interactions.
Potential Side Effects[edit]
As with other tyrosine kinase inhibitors, zipalertinib may cause a range of side effects. Commonly reported adverse effects include fatigue, nausea, and diarrhea. More serious side effects may include cardiotoxicity and hepatotoxicity, which require careful monitoring during treatment.
Research and Future Directions[edit]
Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from zipalertinib therapy. Additionally, studies are exploring the combination of zipalertinib with other therapeutic agents to enhance its efficacy and overcome resistance mechanisms.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
